RVX000222 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
19ライソゾーム病1

19. ライソゾーム病


臨床試験数 : 899 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03228940
(ClinicalTrials.gov)
September 30, 201918/7/2017Safety and Effect of Oral RVX000222 in Subjects With Fabry DiseaseAn Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry DiseaseFabry DiseaseDrug: RVX000222Resverlogix CorpNULLNot yet recruiting18 Years75 YearsAll16Phase 1/Phase 2Canada